ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known. Chronic and acute inflammation is the cause of countless diseases and premature death. As a result, containment, control or prevention of inflammation is, without question, one of the most important, universal health care objectives.

In the short term, ProtoKinetix is undertaking a series of independent tests towards the development of a disease specific therapeutic program. ProtoKinetix is embarking on the structuring of a partnership / licensing agreement to develop treatments for autoimmune diseases and chronic conditions. As an example, the inflammation of the pancreatic cells that produce insulin is now recognized as the cause of Diabetes.

This new direction of focus for ProtoKinetix has been made possible by the successful economic scale up of production of AAGP™ and the evaluation of the extensive testing done to date. The Company will now be in a position to better satisfy the testing demands throughout the world.

To date, medicine had limited options available in the treatment and containment of chronic inflammation. ProtoKinetix strongly believes that the AAGP™ family of molecules will prove to be a powerful therapeutic agent against all inflammatory diseases.